Scientific Poster: Troponin I Concordance Between POC and Laboratory-Based Systems

Author: C. Bethoney; Presented at IFCC-EuroMedLab 2017

Christina Bethoney |
Jun 20, 2017

Objective:The objective of this study was to demonstrate diagnostic equivalence between the cardiac troponin I (cTnI) method on the point-of-care Stratus® CS/Stratus CS 200* Acute Care™ Diagnostic Systems and the laboratory-based ADVIA Centaur® TnI-Ultra® assay on the ADVIA Centaur XP Immunoassay System (all from Siemens Healthcare Diagnostics Inc.) in the determination of myocardial infarction (MI).

Relevance:Troponin is recognized as the preferred biomarker in detection of MI given its high clinical sensitivity and myocardial tissue specificity. The Third Universal Definition of MI, endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF) and adopted by the World Health Organization (WHO), requires at least one cTnI value above the 99th percentile upper reference limit (URL) during patient monitoring for detection of MI. The cTnI methods on the Stratus CS/Stratus CS 200* and ADVIA Centaur XP systems are considered guideline-acceptable as they each display optimal precision at their 99th percentile URL with a coefficient of variation (CV) ≤10%, allowing reliable detection of changing cTnI values.

Share this page:

Related Articles

Acute Care, ADVIA Centaur, Stratus, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners. *Stratus CS 200 Acute Care Diagnostic System is not available for sale in the U.S. Product availability varies by country.Product availability may vary from country to country and is subject to varying regulatory requirements.